Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Johnson and Johnson
Merck
McKinsey
Express Scripts

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Iloprost - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic drug sources for iloprost and what is the scope of freedom to operate?

Iloprost is the generic ingredient in one branded drug marketed by Actelion Pharms Ltd and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are four drug master file entries for iloprost. One supplier is listed for this compound.

Recent Clinical Trials for iloprost

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Innovation Fund DenmarkPhase 2/Phase 3
Jakob Stensballe, MD, PhDPhase 2/Phase 3
Independent Research Fund DenmarkPhase 2/Phase 3

See all iloprost clinical trials

Pharmacology for iloprost
Drug ClassProstacycline
Medical Subject Heading (MeSH) Categories for iloprost
Synonyms for iloprost
(16R,S)-Methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I(sub 2)
(16R,S)-methyl-18,18,19,19-tetradehydro-6a-carbaprostaglandin I2
(1S,2R,3R,5S)-7-[(E)-4-Carboxybutylidene]-2-[(3S,1E)-3-hydroxy-4-methyl-6-octyn-1-enyl]-bicyclo[3.3.0]octane
(1S,2R,3R,5S)-7-[(E)-4-carboxybutylidene]-2-[(3S,1E)-3-hydroxy-4-methyl-6-octyne-1-enyl]-3-hydroxybicyclo[3.3.0]octane
(5E)-5-((3aS,4R,5R,6aS)-5-Hydroxy-4-((1E,3S,4R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)hexahydropentalen-2(1H)-ylidene)pentanoic acid
(5e)-5-[(3as,4r,5r,6as)-5-Hydroxy-4-[(1e,3s,4r)-3-Hydroxy-4-Methyloct-1-En-6-Yn-1-Yl]hexahydropentalen-2(1h)-Ylidene]pentanoic Acid
(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid
(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyl-oct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5E)-5-[(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]-2(1H)-pentalenylidene]pentanoic Acid
(5E)-5-[(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-ynyl]-2(1H)-pentalenylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-4-[(E,3S)-4-methyl-3-oxidanyl-oct-1-en-6-ynyl]-5-oxidanyl-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]hexahydropentalen-2(1H)-ylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyl-oct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(5E)-5-[(3aS,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
(E)-(3aS,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-ynyl)-delta(sup 2(1H),delta)-pentalenevaleric acid
(E)-5-((3aS,4R,5R,6aS)-5-hydroxy-4-((3S,E)-3-hydroxy-4-methyloct-1-en-6-ynyl)hexahydropentalen-2(1H)-ylidene)pentanoic acid
(E)-5-(3aS,4R,5R,6aS)-5-Hydroxy-4((E)-(3S,4RS)-3-hydroxy-4-methyl-1-octen-6-inyl)perhydropentalen-2-yliden)valeriansaeure
(Z)-5-((3aS,4R,5R,6aS)-5-hydroxy-4-((3S,E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)hexahydropentalen-2(1H)-ylidene)pentanoic acid
[3H]-Iloprost
1212AH
16(R)-Iloprost
5-((3aS,5R,6aS,E)-5-hydroxy-4-((3S,E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl)hexahydropentalen-2(1H)-ylidene)pentanoic acid
5-[(2E,3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-octahydropentalen-2-ylidene]pentanoic acid
5-[[(2E,3aS,4R,5R,6aS)-Octahydro-5-hydroxy-4-[(1E,3S,4R)-3-hydroxy-4-methyl-1-octene-6-ynyl]pentalene]-2-ylidene]pentanoic acid
6,9.alpha.-Methylene-11.alpha.,15S-dihydroxy-16-methyl-prosta-5E,13E-dien-18-yn-1-oic acid
73873-87-7
74843-13-3
78919-13-8
A839531
AC-6105
AC1NSK5T
AC1O5JP3
AC1Q1J28
AHG2128QW6
AKOS024456922
AKOS025402197
AN-10394
AN-36592
B6933
BAY Q6256
BAY-q-6256
BC682483
BCP05834
BDBM23954
BRD-A45664787-001-01-4
BRD-A45664787-001-02-2
C22H32O4
CAS-78919-13-8
CHEBI:63916
CHEMBL494
Ciloprost
CS-5586
CTK8G0274
D02721
DB01088
DSSTox_CID_21046
DSSTox_GSID_41046
DSSTox_RID_79616
DTXSID2041046
Endoprost
GTPL1895
HIFJCPQKFCZDDL-ACWOEMLNSA-N
HIFJCPQKFCZDDL-JYTNZNGZSA-N
HMS2090A19
HMS3650E08
HY-A0096
IL2
Ilomedin
Ilomedine
Iloprost (USAN/INN)
Iloprost [BAN:INN]
Iloprost [USAN:INN:BAN]
Iloprost R-isomer
Iloprost, >=98% (HPLC)
Iloprostum
Iloprostum [Latin]
J-502615
K395
KS-00001F60
LS-101845
MolPort-023-276-312
MolPort-039-138-876
NCGC00181784-01
PDSP2_001536
Pentanoic acid, 5-((3aS,4R,5R,6aS)-hexahydro-5-hydroxy-4-((1E,3S,4R)-3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene)-, (5E)-
Pentanoic acid, 5-(hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene)-
Pentanoic acid,5-[(3aS,4R,5R,6aS)-hexahydro-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyl-1-octen-6-yn-1-yl]-2(1H)-pentalenylidene]-,(5E)-
RP17693
SCHEMBL13386495
SCHEMBL13386497
SCHEMBL4357
SCHEMBL532499
SCHEMBL6083382
SH-401
SR-01000946274
SR-01000946274-1
SR-05000001498
SR-05000001498-1
SR-05000001498-2
Tox21_113586
UNII-AHG2128QW6
UNII-JED5K35YGL component HIFJCPQKFCZDDL-GBSCXWAGSA-N
Ventavis
Ventavis (TN)
ZINC3784120
ZK 00036374
ZK 36374
ZK-00036374
ZK-36374
ZK-363775

US Patents and Regulatory Information for iloprost

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actelion Pharms Ltd VENTAVIS iloprost SOLUTION;INHALATION 021779-001 Dec 29, 2004 DISCN No No   Start Trial   Start Trial   Start Trial
Actelion Pharms Ltd VENTAVIS iloprost SOLUTION;INHALATION 021779-003 Aug 7, 2009 RX Yes Yes   Start Trial   Start Trial   Start Trial
Actelion Pharms Ltd VENTAVIS iloprost SOLUTION;INHALATION 021779-002 Dec 8, 2005 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
AstraZeneca
McKesson
Medtronic
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.